F. Tanaka

发表

Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer

H. Wada, K. Takenaka, Y. Otake, 2004, Annals of Surgical Oncology.

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)

T. Yamanaka, M. Satouchi, K. Yoh, 2018, Journal of Thoracic Oncology.

Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1‐cell adhesion molecule) on resected small cell lung cancer specimens: In relation to proliferation state

H. Wada, F. Tanaka, T. Nakagawa, 2001, Journal of surgical oncology.

A case of achondroplasia with downward displacement of the brain stem

J. Konishi, R. Asato, F. Tanaka, 1995, Neuroradiology.

Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC).

H. Wada, F. Tanaka, T. Shoji, 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.

H. Wada, F. Tanaka, M. Li, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of tracheo-bronchial wall invasion using transbronchial ultrasonography (TBUS).

H. Wada, F. Tanaka, M. Imamura, 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy.

H. Wada, F. Tanaka, O. Ike, 1995, Lung cancer.

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).

H. Wada, F. Tanaka, R. Miyahara, 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816

S. Broderick, T. Mitsudomi, J. Neely, 2023, Journal of Thoracic Oncology.

Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend.

H. Wada, F. Tanaka, T. Nakagawa, 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer.

H. Wada, F. Tanaka, M. Li, 2000, Cancer research.

A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.

N. Tsubota, H. Wada, F. Tanaka, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer.

H. Wada, F. Tanaka, M. Li, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC).

H. Wada, F. Tanaka, T. Shoji, 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

M. Sonobe, T. Manabe, H. Wada, 2005, British Journal of Cancer.

Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

H. Wada, F. Tanaka, K. Yanagihara, 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Time trends and survival after operations for primary lung cancer from 1976 through 1990.

H. Wada, F. Tanaka, O. Ike, 1996, The Journal of thoracic and cardiovascular surgery.

Lewis Y antigen expression and postoperative survival in non-small cell lung cancer.

H. Wada, F. Tanaka, K. Yanagihara, 1998, The Annals of thoracic surgery.

The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.

M. Fukushima, H. Wada, F. Tanaka, 2000, Current pharmaceutical biotechnology.

Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients

T. Manabe, H. Wada, F. Tanaka, 2004, British Journal of Cancer.